Evolent Health Inc - A (EVH) 13F Filing Data & Analysis (Q2 2026)

EVH ranks #2986 out of 37501 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

EVH is a top-conviction position for Rubicon Founders LLC — at 16.1% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

The largest dollar stake in EVH belongs to BlackRock, Inc., but the position matters far more to Rubicon Founders LLC, who has 16.1% of their own portfolio riding on it — a reminder that the biggest holder by size and the holder with the biggest bet aren't always the same fund.

Marshall Wace, LLP has added to its EVH position for two straight quarters, increasing it by $17.5M to reach $18.5M today.

JPMorgan has trimmed its EVH position for two straight quarters, cutting it by $11.4M while still holding $352.3K.

EVH is down 1.2% today, but institutions show net buying of $60.6M this quarter — a divergence between today's price move and the underlying institutional flow.

EVH reported a net loss of $505.0M over the trailing twelve months.

• Not yet profitable — net loss of $505.0M over the trailing twelve months
• Revenue declined 4.5% year over year
• Net income declined year over year, from -$130.5M to -$505.0M
• Generated $38.8M in positive operating cash flow
• Current ratio of 1.31x — below the conventional 1.5x liquidity buffer
• Liabilities run 3.57x equity — a highly leveraged balance sheet worth noting